Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy

John B.A.G. Haanen(B. J. Medical College & Sassoon Hospital), Michel Obéid(University Hospital of Lausanne), Alexander M. Menzies(The University of Sydney), Petros Grivas(Fred Hutch Cancer Center), John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Igor Puzanov(Vanderbilt University Medical Center), Solange Peters(University Hospital of Lausanne), James Larkin(Trinity College Dublin), Marc S. Ernstoff(Roswell Park Comprehensive Cancer Center), Yinghong Wang(The University of Texas MD Anderson Cancer Center)
Annals of Oncology
March 17, 2020
10.1016/j.annonc.2020.03.285
Cited by 230

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k